Alzheimer’s drug rejected for NHS use ‘slows disease’ by eight years

Credit: ClarkandCompany

By Ella Pickover, PA

The Alzheimer’s drug Lecanemab, which has been rejected for NHS use, can slow disease progression by eight years, researchers claim.

The medication has been licensed for use in the UK, but will not be made available on the NHS after the spending watchdog deemed the benefits “too small” to justify the cost.